How effective is the TB vaccine for adults compared to children? 

The Bacillus Calmette-Guérin (BCG) vaccine remains the only available immunisation against tuberculosis (TB) and has been used globally for over a century. While it is a vital tool in public health, its ability to prevent the disease varies significantly depending on the age of the person receiving it and the specific form of tuberculosis being targeted. In the United Kingdom, vaccination policy has shifted from a universal schools-based programme to a targeted approach that prioritises those at the highest risk. Understanding the differences in effectiveness between children and adults is essential for clinicians and the public to manage expectations regarding the level of protection provided by a single dose. 

What We’ll Discuss in This Article 

• The protective efficacy of the BCG vaccine in infants and young children. 

• Why the vaccine is less effective at preventing pulmonary tuberculosis in adults. 

• The clinical reasons for the UK age limit of 35 for BCG vaccination. 

• How the BCG vaccine interacts with prior exposure to other bacteria. 

• The role of the Mantoux test in assessing eligibility for the vaccine. 

• The history of the UK schools-based tuberculosis vaccination programme. 

Efficacy in babies and young children 

The BCG vaccine is most reliable when administered to infants and very young children, particularly in its ability to prevent the most dangerous forms of the disease. Clinical evidence demonstrates that the BCG vaccine is 70 to 80 percent effective against the most severe forms of TB, such as TB meningitis in children. These life-threatening conditions occur when the bacteria spread from the lungs to the brain or the bloodstream. By providing high levels of protection against these disseminated forms of the disease, the vaccine significantly reduces childhood mortality in areas where tuberculosis is prevalent. Because children are more prone to these severe, rapidly progressing complications, neonatal vaccination remains a cornerstone of the NHS strategy for at-risk families. 

Protection against pulmonary tuberculosis in adults 

While the BCG vaccine is highly effective at preventing severe complications in the young, its ability to prevent the most common form of the disease pulmonary tuberculosis in the lungs is much more variable in adults. In many adult populations, the vaccine has been shown to offer inconsistent protection against the respiratory form of the infection. The BCG vaccine doesn’t protect against TB that causes lung disease in adults and it does not prevent the initial infection with the bacteria. Because pulmonary TB is the primary way the disease is spread through the community via respiratory droplets, the vaccine’s limited effectiveness in this area means it cannot be used as a standalone tool to eliminate tuberculosis from a population. This variability in adult protection is one of the main reasons the UK focuses on early detection and treatment rather than universal adult vaccination. 

Clinical age limits and evidence in the UK 

The NHS and NICE guidelines currently set a clear age limit for when the BCG vaccine is typically offered, based on a lack of evidence for its effectiveness in older age groups. BCG vaccination is rarely given to anyone over the age of 16 and never over the age of 35 because it doesn’t work very well in adults. For individuals over the age of 35, there is virtually no clinical data to support that the vaccine provides any meaningful protection against tuberculosis. Consequently, adult vaccination in the UK is strictly limited to those aged 16 to 35 who have an increased occupational risk, such as healthcare workers, laboratory staff, or those working with vulnerable populations in prisons or homeless hostels. 

The role of prior exposure and the Mantoux test 

One reason for the varied effectiveness of the BCG vaccine in adults compared to infants is the likelihood of prior exposure to environmental mycobacteria or the tuberculosis bacteria itself. In infants, the immune system is “naive,” meaning it has not yet encountered these bacteria, allowing the vaccine to provide a clean and effective immune response. As individuals age, they are more likely to have been exposed to various mycobacteria found in the environment, which can interfere with the vaccine’s ability to stimulate the correct immune response. This is why anyone over the age of six in the UK must undergo a Mantoux skin test before receiving the BCG vaccine. If the test is positive, it means the person already has an immune response to the bacteria, and the vaccination would be both unnecessary and potentially lead to a more severe local skin reaction. 

Comparison of BCG Effectiveness by Age Group 

Feature	Infants and Young Children	Adults (16 to 35)	Adults (Over 35)
Severe Forms (e.g. Meningitis)	70% to 80% effective	Evidence is limited	No proven benefit
Pulmonary TB (Lung disease)	Consistently high protection	Highly variable (0% to 80%)	No proven benefit
Primary Goal	Prevent life-threatening illness	Occupational protection	Not recommended
Mantoux Test Required?	Only if over 6 or lived abroad	Yes, always required	N/A
Duration of Protection	Estimated 10 to 15 years	Estimated 10 to 15 years	N/A

The history of universal vaccination in the UK 

The shift in UK policy from universal to targeted vaccination was largely influenced by the changing epidemiology of the disease and the specific way the vaccine works in different age groups. From 1953 until 2005, the BCG vaccine was offered to all children in the UK at around age 13 or 14. This “schools programme” was designed to protect young adults as they entered the workforce. However, as tuberculosis rates fell significantly among the UK-born population, the benefit of vaccinating every teenager became less clear. Public health authorities determined that focusing resources on high-risk newborns provided better protection for the most vulnerable members of society. This targeted approach ensures that those most likely to be exposed to the bacteria are protected early in life, when the vaccine is at its most effective. 

Conclusion 

The BCG vaccine is a highly effective intervention for protecting children against the most severe forms of tuberculosis, but it offers limited and variable protection for adults against lung-based disease. In the United Kingdom, clinical evidence supports the use of the vaccine primarily in infants and children at high risk, with adult vaccination reserved for specific occupational groups under the age of 35. Because the vaccine does not reliably prevent pulmonary tuberculosis in adults, the NHS prioritises a combination of targeted immunisation and rapid diagnostic testing to manage the disease effectively across all communities. 

If you experience severe, sudden, or worsening symptoms, such as a severe allergic reaction or sudden difficulty breathing following a vaccination, call 999 immediately. 

Authority Snapshot (E-E-A-T Block) 

This article provides a clinical comparison of the BCG vaccine’s effectiveness across different age groups, based on United Kingdom medical standards. All information is strictly aligned with the current evidence-based guidelines provided by the NHS, the National Institute for Health and Care Excellence (NICE), and the UK Health Security Agency. The content has been produced by a dedicated medical writing team and reviewed by Dr. Stefan Petrov, a UK-trained physician, to ensure clinical accuracy and patient safety.